Company
Headquarters: Sydney, NSW, Australia
Founded: 1987. Parts of the company have operated for many decades
Employees: 38,000
CEO: Dr. Colin Stephen Goldschmidt
A$12.36 Billion
AUD as of July 1, 2024
US$8.23 Billion
Sonic Healthcare Limited is a medical company specializing in diagnostics services. It provides services in pathology/laboratory medicine and imaging/radiology. Having grown through international acquisitions, Sonic Healthcare now operates in Australia, New Zealand, United States, United Kingdom, Germany, Switzerland, Belgium, and Ireland
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Sonic Healthcare Limited offers medical diagnostic services in Australia. The company provides laboratory medicine/pathology; diagnostic imaging/radiology, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry; and primary care medical services comprising general practice services, occupational health services, remote health services, community and home nursing services, primary care research programs, health assessment technologies, clinical trials, and chronic disease management programs to clinicians, hospitals, community health services, and their patients. It also offers administrative services and facilities to medical practitioners. The company operates in Australia, New Zealand, the United Kingdom, the United States, Germany, Switzerland, Belgium, and Ireland. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Sonic Healthcare Limited has the following listings and related stock indices.
Stock: ASX: SHL wb_incandescent
Pathology/laboratory medicine and Imaging/radiology
Dr Colin Goldschmidt (CEO, Managing Director)
Revenue: A$6.2 billion (2019)